[8-K] GE Aerospace Reports Material Event
On 24 Jul 2025 Kestra Medical Technologies (KMTS) director Raymond W. Cohen filed Form 4 disclosing the automatic conversion and acquisition of 12,994 restricted common shares. The shares arose from previously granted Class A units of West Affum Holdings that converted in conjunction with the company鈥檚 IPO; therefore, no cash consideration was paid (transaction code 鈥淎鈥�). After the event, Cohen鈥檚 beneficial ownership stands at 12,994 KMTS shares held directly.
The award vests in three tranches: 4,331 shares vested immediately on 24 Jul 2025; an additional 4,331 will vest on 24 Jul 2026; and the remaining 4,332 will vest on 24 Jul 2027. The filing shows no open-market purchases, sales, option activity, or derivative positions, and it contains no financial performance metrics.
While the transaction modestly increases insider alignment, the share amount is relatively small and is unlikely to be market-moving by itself.
Il 24 luglio 2025, il direttore di Kestra Medical Technologies (KMTS), Raymond W. Cohen, ha presentato il Modulo 4 comunicando la conversione automatica e l'acquisizione di 12.994 azioni ordinarie vincolate. Le azioni derivano da unit脿 di Classe A di West Affum Holdings precedentemente assegnate, che sono state convertite in concomitanza con l'IPO della societ脿; pertanto, non 猫 stato pagato alcun corrispettivo in denaro (codice transazione 鈥淎鈥�). Dopo l鈥檕perazione, la propriet脿 effettiva di Cohen 猫 di 12.994 azioni KMTS detenute direttamente.
Il premio si matura in tre tranche: 4.331 azioni sono maturate immediatamente il 24 luglio 2025; ulteriori 4.331 azioni matureranno il 24 luglio 2026; e le restanti 4.332 azioni matureranno il 24 luglio 2027. La dichiarazione non mostra acquisti o vendite sul mercato aperto, attivit脿 di opzioni o posizioni derivate, n茅 contiene metriche di performance finanziaria.
Pur aumentando modestamente l鈥檃llineamento degli insider, la quantit脿 di azioni 猫 relativamente piccola e difficilmente avr脿 un impatto significativo sul mercato da sola.
El 24 de julio de 2025, el director de Kestra Medical Technologies (KMTS), Raymond W. Cohen, present贸 el Formulario 4 revelando la conversi贸n autom谩tica y adquisici贸n de 12,994 acciones ordinarias restringidas. Las acciones provienen de unidades de Clase A de West Affum Holdings previamente otorgadas que se convirtieron junto con la oferta p煤blica inicial de la compa帽铆a; por lo tanto, no se pag贸 contraprestaci贸n en efectivo (c贸digo de transacci贸n 鈥淎鈥�). Tras el evento, la propiedad beneficiaria de Cohen es de 12,994 acciones KMTS mantenidas directamente.
La concesi贸n se consolida en tres tramos: 4,331 acciones se consolidaron inmediatamente el 24 de julio de 2025; otras 4,331 se consolidar谩n el 24 de julio de 2026; y las restantes 4,332 se consolidar谩n el 24 de julio de 2027. La presentaci贸n no muestra compras o ventas en el mercado abierto, actividad de opciones o posiciones derivadas, ni contiene m茅tricas de rendimiento financiero.
Si bien la transacci贸n aumenta modestamente la alineaci贸n de los insiders, la cantidad de acciones es relativamente peque帽a y es poco probable que por s铆 sola mueva el mercado.
2025雲� 7鞗� 24鞚�, Kestra Medical Technologies(KMTS) 鞚挫偓 Raymond W. Cohen鞚� 鞛愲彊 鞝勴櫂 氚� 12,994欤检潣 鞝滍暅霅� 氤错喌欤� 旆摑鞚� 瓿店皽頃橂姅 Form 4毳� 鞝滌稖頄堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 須岇偓鞚� IPO鞕� 頃粯 鞝勴櫂霅� West Affum Holdings鞚� 鞚挫爠鞐� 攵�鞐悳 Class A 雼渼鞐愳劀 氚滌儩頄堨溂氅�, 霐半澕靹� 順勱笀 雽�臧�電� 歆�旮夒悩歆� 鞎婌晿鞀惦媹雼�(瓯半灅 旖旊摐 鈥淎鈥�). 鞚� 瓯半灅 頉� Cohen鞚� 鞁れ 靻岇湢 欤检嫕 靾橂姅 歆侅爲 氤挫湢頃� 12,994欤� KMTS 欤检嫕鞛呺媹雼�.
靾橃棳 欤检嫕鞚� 靹� 氩堨棎 雮橂垊鞏� 甓岆Μ臧� 氚滌儩頃╇媹雼�: 4,331欤茧姅 2025雲� 7鞗� 24鞚� 歃夓嫓 甓岆Μ臧� 氚滌儩頃橂┌, 於旉皜搿� 4,331欤茧姅 2026雲� 7鞗� 24鞚检棎, 雮橂ǜ歆� 4,332欤茧姅 2027雲� 7鞗� 24鞚检棎 甓岆Μ臧� 氚滌儩頃╇媹雼�. 鞝滌稖 靹滊鞐愲姅 瓿店皽 鞁滌灔鞐愳劀鞚� 毵れ垬, 毵る弰, 鞓奠厴 頇滊彊 霕愲姅 韺岇儩靸來拡 韽靺橃澊 鞐嗢溂氅�, 鞛 靹标臣 歆�響滊弰 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
鞚措矆 瓯半灅電� 雮措秬鞛� 鞝曤牞鞚� 雼れ唽 雴掛澊歆�毵�, 欤检嫕 靾橁皜 牍勱祼鞝� 鞝侅柎 雼弲鞙茧 鞁滌灔鞐� 韥� 鞓來枼鞚� 氙胳箻旮半姅 鞏措牑鞖� 瓴冹溂搿� 氤挫瀰雼堧嫟.
Le 24 juillet 2025, le directeur de Kestra Medical Technologies (KMTS), Raymond W. Cohen, a d茅pos茅 le Formulaire 4 r茅v茅lant la conversion automatique et l鈥檃cquisition de 12 994 actions ordinaires restreintes. Ces actions proviennent d鈥檜nit茅s de Classe A de West Affum Holdings pr茅c茅demment attribu茅es, converties lors de l鈥檌ntroduction en bourse de la soci茅t茅 ; aucune contrepartie en esp猫ces n鈥檃 donc 茅t茅 vers茅e (code de transaction 芦 A 禄). Apr猫s cet 茅v茅nement, Cohen d茅tient 12 994 actions KMTS en propri茅t茅 directe.
La r茅compense est acquise en trois tranches : 4 331 actions ont 茅t茅 acquises imm茅diatement le 24 juillet 2025 ; 4 331 autres seront acquises le 24 juillet 2026 ; et les 4 332 restantes le 24 juillet 2027. Le d茅p么t ne montre aucune activit茅 d鈥檃chat ou de vente sur le march茅 libre, ni d鈥檕ptions ou de positions d茅riv茅es, et ne contient aucune m茅trique de performance financi猫re.
Bien que la transaction augmente modestement l鈥檃lignement des initi茅s, le nombre d鈥檃ctions reste relativement faible et est peu susceptible d鈥檃voir un impact significatif sur le march茅 脿 lui seul.
Am 24. Juli 2025 reichte Kestra Medical Technologies (KMTS) Direktor Raymond W. Cohen das Formular 4 ein, in dem die automatische Umwandlung und der Erwerb von 12.994 eingeschr盲nkten Stammaktien offengelegt wurden. Die Aktien stammen aus zuvor gew盲hrten Class A Einheiten von West Affum Holdings, die im Zuge des B枚rsengangs des Unternehmens umgewandelt wurden; daher wurde keine Barzahlung geleistet (Transaktionscode 鈥濧鈥�). Nach dem Ereignis h盲lt Cohen 12.994 KMTS-Aktien direkt.
Die Zuteilung erfolgt in drei Tranchen: 4.331 Aktien wurden am 24. Juli 2025 sofort 眉bertragen; weitere 4.331 Aktien werden am 24. Juli 2026 眉bertragen; und die restlichen 4.332 Aktien am 24. Juli 2027. Die Einreichung zeigt keine K盲ufe oder Verk盲ufe am offenen Markt, keine Optionsaktivit盲ten oder Derivatpositionen und enth盲lt keine finanziellen Leistungskennzahlen.
Obwohl die Transaktion die Insiderbindung leicht erh枚ht, ist die Aktienmenge relativ gering und wird wahrscheinlich allein keinen marktrelevanten Einfluss haben.
- Director ownership increase: Cohen now holds 12,994 KMTS shares, enhancing alignment with public shareholders.
- Limited immediacy: Only 4,331 shares are currently vested; 66% remain restricted until 2026-2027.
Insights
TL;DR: Routine IPO-related share conversion; aligns director but immaterial to valuation.
The Form 4 records a non-cash grant that brings Cohen鈥檚 direct stake to 12,994 shares. Given KMTS鈥檚 likely post-IPO float, this holding is negligible from a supply-demand standpoint. The staged vesting maintains long-term alignment but also limits immediate tradable float. No buy/sell signals or valuation insight can be drawn; therefore impact on stock price should be neutral.
TL;DR: Standard equity incentive; positive alignment, but governance impact modest.
The conversion follows typical IPO clean-up mechanics, shifting partnership units into listed equity. Multi-year vesting supports retention and aligns director incentives with shareholder value creation through 2027. No red flags鈥攁uthority covered by existing PoA. However, the quantum is small, so governance leverage remains limited.
Il 24 luglio 2025, il direttore di Kestra Medical Technologies (KMTS), Raymond W. Cohen, ha presentato il Modulo 4 comunicando la conversione automatica e l'acquisizione di 12.994 azioni ordinarie vincolate. Le azioni derivano da unit脿 di Classe A di West Affum Holdings precedentemente assegnate, che sono state convertite in concomitanza con l'IPO della societ脿; pertanto, non 猫 stato pagato alcun corrispettivo in denaro (codice transazione 鈥淎鈥�). Dopo l鈥檕perazione, la propriet脿 effettiva di Cohen 猫 di 12.994 azioni KMTS detenute direttamente.
Il premio si matura in tre tranche: 4.331 azioni sono maturate immediatamente il 24 luglio 2025; ulteriori 4.331 azioni matureranno il 24 luglio 2026; e le restanti 4.332 azioni matureranno il 24 luglio 2027. La dichiarazione non mostra acquisti o vendite sul mercato aperto, attivit脿 di opzioni o posizioni derivate, n茅 contiene metriche di performance finanziaria.
Pur aumentando modestamente l鈥檃llineamento degli insider, la quantit脿 di azioni 猫 relativamente piccola e difficilmente avr脿 un impatto significativo sul mercato da sola.
El 24 de julio de 2025, el director de Kestra Medical Technologies (KMTS), Raymond W. Cohen, present贸 el Formulario 4 revelando la conversi贸n autom谩tica y adquisici贸n de 12,994 acciones ordinarias restringidas. Las acciones provienen de unidades de Clase A de West Affum Holdings previamente otorgadas que se convirtieron junto con la oferta p煤blica inicial de la compa帽铆a; por lo tanto, no se pag贸 contraprestaci贸n en efectivo (c贸digo de transacci贸n 鈥淎鈥�). Tras el evento, la propiedad beneficiaria de Cohen es de 12,994 acciones KMTS mantenidas directamente.
La concesi贸n se consolida en tres tramos: 4,331 acciones se consolidaron inmediatamente el 24 de julio de 2025; otras 4,331 se consolidar谩n el 24 de julio de 2026; y las restantes 4,332 se consolidar谩n el 24 de julio de 2027. La presentaci贸n no muestra compras o ventas en el mercado abierto, actividad de opciones o posiciones derivadas, ni contiene m茅tricas de rendimiento financiero.
Si bien la transacci贸n aumenta modestamente la alineaci贸n de los insiders, la cantidad de acciones es relativamente peque帽a y es poco probable que por s铆 sola mueva el mercado.
2025雲� 7鞗� 24鞚�, Kestra Medical Technologies(KMTS) 鞚挫偓 Raymond W. Cohen鞚� 鞛愲彊 鞝勴櫂 氚� 12,994欤检潣 鞝滍暅霅� 氤错喌欤� 旆摑鞚� 瓿店皽頃橂姅 Form 4毳� 鞝滌稖頄堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 須岇偓鞚� IPO鞕� 頃粯 鞝勴櫂霅� West Affum Holdings鞚� 鞚挫爠鞐� 攵�鞐悳 Class A 雼渼鞐愳劀 氚滌儩頄堨溂氅�, 霐半澕靹� 順勱笀 雽�臧�電� 歆�旮夒悩歆� 鞎婌晿鞀惦媹雼�(瓯半灅 旖旊摐 鈥淎鈥�). 鞚� 瓯半灅 頉� Cohen鞚� 鞁れ 靻岇湢 欤检嫕 靾橂姅 歆侅爲 氤挫湢頃� 12,994欤� KMTS 欤检嫕鞛呺媹雼�.
靾橃棳 欤检嫕鞚� 靹� 氩堨棎 雮橂垊鞏� 甓岆Μ臧� 氚滌儩頃╇媹雼�: 4,331欤茧姅 2025雲� 7鞗� 24鞚� 歃夓嫓 甓岆Μ臧� 氚滌儩頃橂┌, 於旉皜搿� 4,331欤茧姅 2026雲� 7鞗� 24鞚检棎, 雮橂ǜ歆� 4,332欤茧姅 2027雲� 7鞗� 24鞚检棎 甓岆Μ臧� 氚滌儩頃╇媹雼�. 鞝滌稖 靹滊鞐愲姅 瓿店皽 鞁滌灔鞐愳劀鞚� 毵れ垬, 毵る弰, 鞓奠厴 頇滊彊 霕愲姅 韺岇儩靸來拡 韽靺橃澊 鞐嗢溂氅�, 鞛 靹标臣 歆�響滊弰 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.
鞚措矆 瓯半灅電� 雮措秬鞛� 鞝曤牞鞚� 雼れ唽 雴掛澊歆�毵�, 欤检嫕 靾橁皜 牍勱祼鞝� 鞝侅柎 雼弲鞙茧 鞁滌灔鞐� 韥� 鞓來枼鞚� 氙胳箻旮半姅 鞏措牑鞖� 瓴冹溂搿� 氤挫瀰雼堧嫟.
Le 24 juillet 2025, le directeur de Kestra Medical Technologies (KMTS), Raymond W. Cohen, a d茅pos茅 le Formulaire 4 r茅v茅lant la conversion automatique et l鈥檃cquisition de 12 994 actions ordinaires restreintes. Ces actions proviennent d鈥檜nit茅s de Classe A de West Affum Holdings pr茅c茅demment attribu茅es, converties lors de l鈥檌ntroduction en bourse de la soci茅t茅 ; aucune contrepartie en esp猫ces n鈥檃 donc 茅t茅 vers茅e (code de transaction 芦 A 禄). Apr猫s cet 茅v茅nement, Cohen d茅tient 12 994 actions KMTS en propri茅t茅 directe.
La r茅compense est acquise en trois tranches : 4 331 actions ont 茅t茅 acquises imm茅diatement le 24 juillet 2025 ; 4 331 autres seront acquises le 24 juillet 2026 ; et les 4 332 restantes le 24 juillet 2027. Le d茅p么t ne montre aucune activit茅 d鈥檃chat ou de vente sur le march茅 libre, ni d鈥檕ptions ou de positions d茅riv茅es, et ne contient aucune m茅trique de performance financi猫re.
Bien que la transaction augmente modestement l鈥檃lignement des initi茅s, le nombre d鈥檃ctions reste relativement faible et est peu susceptible d鈥檃voir un impact significatif sur le march茅 脿 lui seul.
Am 24. Juli 2025 reichte Kestra Medical Technologies (KMTS) Direktor Raymond W. Cohen das Formular 4 ein, in dem die automatische Umwandlung und der Erwerb von 12.994 eingeschr盲nkten Stammaktien offengelegt wurden. Die Aktien stammen aus zuvor gew盲hrten Class A Einheiten von West Affum Holdings, die im Zuge des B枚rsengangs des Unternehmens umgewandelt wurden; daher wurde keine Barzahlung geleistet (Transaktionscode 鈥濧鈥�). Nach dem Ereignis h盲lt Cohen 12.994 KMTS-Aktien direkt.
Die Zuteilung erfolgt in drei Tranchen: 4.331 Aktien wurden am 24. Juli 2025 sofort 眉bertragen; weitere 4.331 Aktien werden am 24. Juli 2026 眉bertragen; und die restlichen 4.332 Aktien am 24. Juli 2027. Die Einreichung zeigt keine K盲ufe oder Verk盲ufe am offenen Markt, keine Optionsaktivit盲ten oder Derivatpositionen und enth盲lt keine finanziellen Leistungskennzahlen.
Obwohl die Transaktion die Insiderbindung leicht erh枚ht, ist die Aktienmenge relativ gering und wird wahrscheinlich allein keinen marktrelevanten Einfluss haben.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
General Electric Company
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||
| (Address of principal executive offices) | (Zip Code) | |||
(Registrant’s telephone number, including
area code) (
| (Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). | ||
| Emerging growth company | ||
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. | ☐ |
| Item 8.01 | Other Events. |
On July 22, 2025, General Electric Company, operating as GE Aerospace (the “Company”), entered into an underwriting agreement by and among the Company and J.P. Morgan Securities LLC, BofA Securities, Inc., and Morgan Stanley & Co. LLC, as Representatives of the several underwriters named therein (the “Underwriting Agreement”), with respect to the issuance and sale of $1,000,000,000 aggregate principal amount of 4.300% Notes due 2030 (the “2030 Notes”) and $1,000,000,000 aggregate principal amount of 4.900% Notes due 2036 (the “2036 Notes” and, together with the 2030 Notes, the “Notes”).
The Notes were registered under the Company’s Registration Statement on Form S-3 (Registration No. 333-276832) (the “Registration Statement”) filed with the Securities and Exchange Commission on February 2, 2024, as supplemented by a preliminary prospectus supplement, filed with the SEC on July 22, 2025, and a final prospectus supplement, filed with the SEC on July 24, 2025.
The above description of the Underwriting Agreement is a summary only and is qualified in its entirety by reference to the Underwriting Agreement, which is attached as Exhibit 1.1 to this Current Report on Form 8-K. This Current Report on Form 8-K is incorporated by reference into the Registration Statement.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit Number | Description |
| 1.1 | Underwriting Agreement, dated July 22, 2025, by and among General Electric Company and J.P. Morgan Securities LLC, BofA Securities, Inc., and Morgan Stanley & Co. LLC, as Representatives of the several underwriters named therein. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| General Electric Company | |||
| (Registrant) | |||
| Date: July 24, 2025 | /s/ Robert Giglietti | ||
| Robert Giglietti Vice President – Chief Accounting Officer, Controller and Treasurer Principal Accounting Officer |
Source:
FAQ
What did KMTS director Raymond W. Cohen report in the Form 4 filed on July 24, 2025?
How many KMTS shares does Cohen own after the reported transaction?
Was any cash paid for the 12,994 KMTS shares?
What is the vesting schedule for the restricted KMTS shares?
Does the filing indicate insider buying or selling activity?
